Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Inclusion Criteria

- Subjects with type 2 diabetes mellitus

- On a stable regimen of metformin alone, metformin and a DPP4, metformin and a TZD, or
metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization

- Body mass indices > 25 and < 45 kg/m2

- Hemoglobin A1c levels ≥ 7.0% and ≤ 11.0% at screening

- Fasting C-peptide levels ≥ 0.2 nmol/L at screening

- Subject with a history of hypertension must be on a stable antihypertensive treatment
(s) (type of medication, dose, and regimen) for at least 6 weeks prior to the first
dose of investigational product

- Other criteria may apply

Exclusion Criteria

- Subject has type 1 diabetes mellitus or history of type 1 diabetes mellitus

- Subject has had 2 or more emergency room visits or hospitalizations due to poor
glucose control in the 6 months prior to screening

- Poorly controlled hypertension defined as diastolic pressure ≥ 95 mmHg or systolic ≥
155 mmHg (confirmed by a repeat assessment) at screening

- Triglycerides ≥ 400 mg/dL (4.52 mmol/L) at screening

- Use of any known cytochrome P450 (CYP) inducers within 30 days or 5 half-lives
(whichever is longer), prior to receiving the first dose of investigational product.

- Use of any known inhibitors of CYP3A4/P-glycoprotein within the 14 days or 5 half
lives (whichever is longer) prior to receiving the first dose of investigational
product

- Other criteria may apply